EGElias Gialafos

Elias Gialafos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elias Gialafos has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis

    by Fotios Drakopanagiotakis, Ilias Papanikolaou, Theodoros Panou, Elias Gialafos, Nikolaos Kostakis, Konstantinos Chytopoulos, Anastasios Bogiatzis, Paschalis Steiropoulos

    Sarcoidosis is a multisystem granulomatous disorder of uncertain origin which still presents major therapeutic dilemmas. Longstanding dependence on corticosteroids, while effective for acute inflammation, carries considerable adverse effects over time. Advances in deciphering sarcoidosis pathobiology—including aberrant Janus kinase (JAK)- signal transducer and activator of transcription (STAT) signaling, mechanistic target of rapamycin (mTOR)-driven metabolic shifts, Th1/Th17.1 immune skewing, effector T-cell exhaustion, and granuloma-centered cytokine circuits—have revealed several targets for intervention. The treatment options are rapidly changing: the SARCORT trial showed that low-dose prednisolone is non-inferior to higher prednisolone doses; the pivotal PREDMETH trial validated methotrexate as a feasible first-line steroid-sparing option; efzofitimod, a novel immunomodulator targeting neuropilin-2, produced steroid-reducing effects in Phase IIbut not in Phase III trials; and JAK inhibitors are accumulating evidence across cutaneous and systemic presentations. The 2025 World Association for Sarcoidosis and Other Granulomatoses (WASOG) statement supports a move toward earlier steroid-sparing approaches. This review methodically connects sarcoidosis molecular and pathophysiological mechanisms to new targeted treatments, examines clinical trial evidence, and proposes future directions toward biomarker-driven individualized care.


  • Open Access

    Prevalence of thyroid autoantibodies in a large series of sarcoidosis patients: Implications for autoimmune thyroid disease screening.

    by Elias Giallafos, Evangelos Oikonomou, Ourania Katsarou, Lykourgos Kolilekas, Evangelos Markozanes, Kostas Zisimos, Gesthimani Seitaridi, Maria Gazouli, Efrosyni Manali, Spyros Papiris, et al.

    Sarcoidosis is a potentially multisystem granulomatous disease frequently associated with autoimmunity. Previous cohort studies have reported an elevated risk of developing autoimmune thyroid disease (AITD) in sarcoidosis patients. Aim of the study was to assess the prevalence of thyroid autoimmunity in a large, biopsy-proven sarcoidosis cohort and compare it to established general population rates, thereby highlighting the clinical significance of screening. To explore the prevalence of AITD, we examined a cross-sectional cohort of 668 patients with biopsy-proven sarcoidosis. Serum Thyroperoxidase Antibodies (TPOAb) and Thyroglobulin Antibodies (TgAb) were quantified using standard electrochemiluminescence immunoassays (ECLIA). The prevalence of positive thyroid autoantibodies was compared to previously published regional healthy control rates (11.4%, n=1,108) using a two-sample Z-test for comparing two proportions. The overall prevalence of positive thyroid autoantibodies (TPOAb and/or TgAb) in the sarcoidosis cohort (n=668) was found to be 27.4% (95% CI: 21.7%-28.3%). This rate was significantly higher compared to the pooled historical control group prevalence of 11.4% (p < 0.001. The prevalence of positive thyroid autoantibodies in patients with sarcoidosis is significantly elevated compared to the healthy population. This finding underscores the strong autoimmune linkage between sarcoidosis and AITD and supports the recommendation for systematic screening for thyroid autoimmunity in patients diagnosed with sarcoidosis.

  • Open Access

    Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI

    by Elias Giallafos, Evangelos Oikonomou, Niki Lama, Spiros Katsanos, Lykourgos Kolilekas, Evaggelos Markozanes, Varvara Pantoleon, Kostas Zisimos, Ourania Katsarou, Panagiotis Theofilis, et al.

    Background/Objectives: Cardiac sarcoidosis (CS) is a challenging diagnosis due to its subclinical progression and the limitations of existing screening tools. Cardiac magnetic resonance (CMR) and PET/CT imaging have improved diagnosis and detection. Aldosterone, a hormone with known profibrotic effects, may offer additional diagnostic value. We therefore aimed to determine whether plasma aldosterone level is associated with myocardial fibrosis, independent of active inflammation, in CS. Methods: This observational study included 541 patients with biopsy-proven sarcoidosis and preserved left ventricular ejection fraction (LVEF ≥ 50%). All underwent CMR with extracellular volume (ECV) mapping and 18F-FDG PET/CT to assess myocardial fibrosis and inflammation, respectively. Plasma aldosterone levels were also measured. Results: Plasma aldosterone levels were significantly higher in patients with cardiac sarcoidosis (172 [IQR 106–235] pg/mL) compared to those without cardiac involvement (143 [100–205] pg/mL, p = 0.02). Aldosterone was independently associated with the presence of late gadolinium enhancement (LGE) on CMR (OR 1.002 per 1 pg/mL increase; 95% CI 1.001–1.004, p = 0.04) and with higher ECV values (β = 0.008 per 1 pg/mL, p = 0.001). Regression analysis showed that aldosterone is associated with ECV (b-0.009, CI: 0.002–0.016, p = 0.009) and there was no interaction according to LGE status indicating a relationship with diffuse myocardial fibrosis even in the absence of visible scarring. No association was observed with T1-, T2-, or PET/CT-defined inflammation. Conclusions: Plasma aldosterone is a robust marker of myocardial fibrosis in sarcoidosis, particularly in early or subclinical stages. Its correlation with ECV—but not with inflammatory imaging markers—suggests its link with myocardial diffuse fibrotic remodeling before, and independently of, overt scarring or inflammation.


  • Open Access

    Association of non-linear dynamics of heart rate variability with all-cause mortality in patients with sarcoidosis.

    by Elias Giallafos, Ioannis Ilias, Spiros Katsanos, Likourgos Kolilekas, Efrosini Manali, Aglaia Vakrakou, Theodore Papaioannou, Kostas Zisimos, Gethsimani Seitaridi, Giannis Parisis, et al.

    Sarcoidosis (Sarc) is linked to increased morbidity and mortality. While 24-hour ambulatory ECG recording is essential for evaluating patients with cardiac symptoms, the complementary role of heart rate variability (HRV) for risk stratification in Sarc patients remains undefined. The aim of this observational study was the assessment of non-linear indices of HRV as independent predictors of mortality in Sarc. 317 patients with confirmed diagnosis of Sarc, underwent comprehensive conventional cardiac testing, including Cardiac Magnetic Resonance (CMR) with late gadolinium enhancement (LGE). These patients were followed up for all-cause mortality as endpoint. Each patient underwent twenty-four-hour Holter monitoring, from which approximate entropy (APEN), short and long-term detrended fluctuation analysis (DFAα1 and DFAα2, respectively), as well as other HRV parameters, were calculated. The study recruited 317 patients (137 men, 180 women) with a mean age of 48.22 ± 11.88 years. Over a median follow-up period of approximately 48 months, 17 deaths were recorded. Competing risk analysis revealed that decreased DFAα1 was a robust prognostic indicator for increased total mortality. ROC analysis demonstrated that the area under the curve (AUC) of DFAα1 (< 0.95) for predicting mortality was 0.761 (95% confidence interval (CI) = 0.617-0.905). DFAα1 ≥ 0.95 was associated with total mortality (HR = 0.109, 95% CI = 0.033-0.362, P= 0.0003). Evaluation of cardiac autonomic dysfunction by DFAα1 serves as an independent predictor for all-cause mortality in patients with Sarc.

  • Open Access

    The Role of NLRP3 Inflammasome in Type 2 Diabetes Mellitus and Its Macrovascular Complications

    by Konstantinos Karamitsos, Evangelos Oikonomou, Panagiotis Theofilis, Ignatios Ikonomidis, Eva Kassi, Vaia Lambadiari, Elias Gialafos, Aikaterini Tsatsaragkou, Vasiliki-Chara Mystakidi, Konstantinos Zisimos, et al.

    Diabetes Mellitus (DM) is among the most common non-infectious causes of death globally, with Type 2 DM (T2DM) representing the majority of cases. T2DM is primarily characterized by insulin resistance, leading to hyperglycemia and compensatory hyperinsulinemia. Rapid changes in lifestyle, technological advancement, and societal evolution have fueled a global rise in T2DM, making it a major public health concern. The condition is associated with numerous complications—both macrovascular and microvascular—including coronary artery disease, heart failure, chronic kidney disease, and diabetic retinopathy, all of which contribute to increased morbidity and early mortality. Chronic tissue inflammation is now recognized as a key factor in the development of T2DM, with elevated inflammatory markers serving as predictors of the disease. In particular, the NLRP3 inflammasome complex has emerged as a central player in this inflammatory process. NLRP3 acts as an intracellular sensor for danger signals and tissue injury, triggering inflammatory responses and contributing to endothelial dysfunction and T2DM pathogenesis. Its role in linking metabolic stress to inflammation has positioned it as a promising therapeutic target. This review focuses on the mechanisms underlying NLRP3 inflammasome activation and its role in T2DM and related vascular complications. Additionally, it highlights emerging therapies that target NLRP3, offering new potential strategies for the prevention and treatment of T2DM.


  • Open Access

    A Tale of Two Diseases: Decoding Aortic Stenosis and Cardiac Amyloidosis

    by Ioannis Gialamas, George E. Zakynthinos, George Dimeas, Panteleimon Pantelidis, Elias Gialafos, Styliani Brili, Athina Goliopoulou, Ourania Katsarou, Elsi Tryfou, Konstantinos Kalogeras, et al.

    Background/Objectives: Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy caused by transthyretin (TTR) amyloid deposition in the myocardium, increasingly recognized in patients with aortic stenosis (AS). This study aims to investigate the diagnostic challenges and therapeutic strategies for patients with both conditions, focusing on shared pathophysiological mechanisms and key diagnostic indicators. Methods: A multimodal diagnostic approach was applied, utilizing cardiac magnetic resonance (CMR) and bone scintigraphy with technetium-99m-labeled tracers to assess AS patients with suspected ATTR-CA. Clinical signs, such as disproportionate heart failure symptoms, conduction abnormalities, and low-flow, low-gradient AS, were evaluated. Electrocardiographic findings, including low-voltage QRS complexes and pseudo-infarction patterns, were also assessed. Treatment options, including transcatheter aortic valve replacement (TAVR) and emerging pharmacotherapies for ATTR-CA, were analyzed. Results: The study found that ATTR-CA is increasingly prevalent in AS patients, with shared mechanisms like oxidative stress and amyloid-induced tissue remodeling. Key diagnostic signs include disproportionate heart failure symptoms, conduction abnormalities, and specific electrocardiographic patterns. TAVR was effective in both isolated AS and AS with ATTR-CA, although patients with both conditions had a higher risk of heart failure hospitalization and persistent symptoms. Emerging pharmacotherapies, such as TTR stabilizers and gene-silencing agents, showed promise in slowing disease progression. Conclusions: A multimodal diagnostic approach is essential for the early detection of ATTR-CA in AS patients. Combining TAVR with emerging pharmacotherapies may improve long-term outcomes for this high-risk group, enhancing patient care in those with both conditions.


  • Peripheral blood natural killer cells in sarcoidosis are associated with early cardiac involvement

    by Aigli G. Vakrakou, Lykourgos Kolilekas, Niki Lama, Spiros Katsanos, Grigorios Stratakos, Ilias Tsougos, Effrosyni Manali, Eirini Grigoriou, Katherina Psarra, Constantinos Kilidireas, et al.

    Aim: To evaluate the distribution of circulating immune cell subsets in peripheral blood of patients with sarcoidosis and investigate if there is an association with an underlying cardiac involvement.Methods and results: Eighty‐five newly diagnosed treatment‐naïve patients with sarcoidosis (50 women) were included in the study. All patients underwent a thorough cardiac investigation, including cardiac magnetic resonance imaging (CMR). Of all patients, 19 (23.53%) had myocardial involvement, and the NK subpopulation in these patients in peripheral blood was significantly decreased compared to patients without (n = 63, p = 0.001 and p = 0.003 respectively). The absolute number of NKT cells (CD3+CD16/56+) in patients with cardiac involvement was highly correlated with T2 map increased values in MRI (r = −686, p = 0.041) showing that low NKT cell count correlates with the inflammatory process of the heart. No difference in CD19, CD3, CD4, CD8 and CD3−NK cell counts was found between groups. Lung severity was not found to correlate with the number of NK cells.Conclusion: We found that low NK cell count in peripheral blood of patients with sarcoidosis is associated with cardiac involvement, and the number of NK‐T cells correlates with CMR findings indicative of myocardial inflammation. This finding might have a potential clinical application in detecting clinically silent cardiac involvement in sarcoidosis and may also suggest potential targets for therapeutic interventions.


  • Open Access

    Splenic Sarcoidosis revealed during CMR. The unexpected!

    by Niki Lama, Elias Giallafos, Efstratios Karavasilis, Varvara Pantoleon, Maria Mademli, Nikolaos L. Kelekis

    Purpose/Objectives Sarcoidosis is a multi-systematic inflammatory disease, affecting not only the lungs. During CMR studies splenic lesions can be detected incidentally. The aim of our study is to highlight the features of splenic sarcoidosis, revealed to us during Cardiac Magnetic Resonance studies (CMR), providing a differentiation assistance for feature use. Methods &

  • Open Access

    ASSOCIATION OF THE CALCITRIOL TO CALCIFEDIOL RATIO WITH CARDIAC INVOLVEMENT IN NEWLY DIAGNOSED SARCOIDOSIS

    by Elias Gialafos, Lykourgos Kolilekas, Effrosyni Manali, Spyros Katsanos, Paschalis Steiropoulos, Elias Tsougos, Grigorios Stratakos, Mina Gaga, Nikos Koulouris, Spyros Papiris, et al.


  • Open Access

    A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

    by A. G. Vakrakou, D. Tzanetakos, S. Valsami, E. Grigoriou, K. Psarra, J. Tzartos, M. Anagnostouli, E. Andreadou, M. E. Evangelopoulos, G. Koutsis, et al.

    Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16% of treated MS-patients whereas severe neutropenia occurred in 0.6%. Herein, we present the case of a 34-year-old woman with relapsing-remitting MS, with a history of treatment with glatiramer acetate and natalizumab, who subsequently received Alemtuzumab (12 mg / 24 h × 5 days). 70-days after the last Alemtuzumab administration, the patient displayed neutropenia (500 neutrophils/μL) with virtual absence of B-cells (0.6% of total lymphocytes), low values of CD4-T-cells (6.6%) and predominance of CD8-T-cells (48%) and NK-cells (47%); while large granular lymphocytes (LGL) predominated in the blood-smear examination. Due to prolonged neutropenia (5-days) the patient was placed on low-dose corticosteroids leading to sustained remission. This is the first case of a patient with relapsing-remitting MS with neutropenia two months post-Alemtuzumab, with simultaneous presence of LGL cells in the blood and a robust therapeutic response to prednisolone. We recommend testing with a complete blood count every 15 days in the first 3 months after the 1st Alemtuzumab administration and searching for large granular lymphocytes cell expansion on microscopic examination of the peripheral blood if neutropenia develops.